Literature DB >> 25613119

Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers.

Julie Lecarpentier1, Catherine Noguès2, Emmanuelle Mouret-Fourme2, Bruno Buecher3, Marion Gauthier-Villars3, Dominique Stoppa-Lyonnet4, Valérie Bonadona5, Jean-Pierre Fricker6, Pascaline Berthet7, Olivier Caron8, Isabelle Coupier9, Pascal Pujol9, Laurence Faivre10, Paul Gesta11, François Eisinger12, Véronique Mari13, Laurence Gladieff14, Alain Lortholary15, Elisabeth Luporsi16, Dominique Leroux17, Laurence Venat-Bouvet18, Christine M Maugard19, Chrystelle Colas20, Julie Tinat21, Christine Lasset5, Nadine Andrieu22.   

Abstract

BACKGROUND: Mutations in BRCA1/2 confer a high risk of breast cancer, but literature values of this risk vary. A genotype-phenotype correlation has been found in both genes, and the effect of reproductive factors differs according to mutation location. Therefore, we hypothesize that such a variation may exist for other factors related to estrogen exposure.
METHODS: We used a weighted Cox regression model to assess variation in breast cancer risk with these factors using location of mutation in homogeneous breast cancer risk region of BRCA1/2 in the GENEPSO study.
RESULTS: We found that late age at menarche reduced breast cancer risk by 31% and that among BRCA1 carriers, a long or a short menstrual cycle increased risk (by 65% and 73%, respectively). Among premenopausal women, overweight was associated with a 45% decrease in risk whereas underweight was associated with an increased risk (HR, 2.40). A natural menopause, mainly after age 50, was associated with a high breast cancer risk (HR, 2.46), and a significant interaction between menopause status and the location of mutations was found leading up to 10% variation in absolute risk according to the age at menopause.
CONCLUSIONS: As observed in the general population, a late menarche, a long or a short menstrual cycle, over- or underweight, and being postmenopausal were associated with breast cancer risk in BRCA1/2 carriers. The association with the menopause was observed only when the mutation was located in the "high-risk" zones. IMPACT: Taking into account modifier factors, location of mutation might be important for the clinical management of BRCA1/2 mutation carriers. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25613119     DOI: 10.1158/1055-9965.EPI-14-0884

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  7 in total

1.  Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with BRCA1 mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited BRCA1 mutations.

Authors:  Laudine Communal; Myriam Vilasco; Justine Hugon-Rodin; Aurélie Courtin; Najat Mourra; Najiba Lahlou; Morwenna Le Guillou; Muriel Perrault de Jotemps; Marie-Pierre Chauvet; Marc Chaouat; Pascal Pujol; Jean Feunteun; Suzette Delaloge; Patricia Forgez; Anne Gompel
Journal:  Oncotarget       Date:  2016-07-19

2.  Reproductive risk factors associated with breast cancer in women in Bangui: a case-control study.

Authors:  Augustin Balekouzou; Ping Yin; Christian Maucler Pamatika; Cavin Epie Bekolo; Sylvain Wilfrid Nambei; Marceline Djeintote; Komlan Kota; Christian Diamont Mossoro-Kpinde; Chang Shu; Minghui Yin; Zhen Fu; Tingting Qing; Mingming Yan; Jianyuan Zhang; Shaojun Chen; Hongyu Li; Zhongyu Xu; Boniface Koffi
Journal:  BMC Womens Health       Date:  2017-03-06       Impact factor: 2.809

3.  Estrogen reprograms the activity of neutrophils to foster protumoral microenvironment during mammary involution.

Authors:  Hwa Hwa Chung; Yu Zuan Or; Smeeta Shrestha; Jia Tong Loh; Chew Leng Lim; Zoe Ong; Amanda Rui En Woo; I-Hsin Su; Valerie C L Lin
Journal:  Sci Rep       Date:  2017-04-21       Impact factor: 4.379

4.  GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers.

Authors:  Fabienne Lesueur; Noura Mebirouk; Yue Jiao; Laure Barjhoux; Muriel Belotti; Maïté Laurent; Mélanie Léone; Claude Houdayer; Brigitte Bressac-de Paillerets; Dominique Vaur; Hagay Sobol; Catherine Noguès; Michel Longy; Isabelle Mortemousque; Sandra Fert-Ferrer; Emmanuelle Mouret-Fourme; Pascal Pujol; Laurence Venat-Bouvet; Yves-Jean Bignon; Dominique Leroux; Isabelle Coupier; Pascaline Berthet; Véronique Mari; Capucine Delnatte; Paul Gesta; Marie-Agnès Collonge-Rame; Sophie Giraud; Valérie Bonadona; Amandine Baurand; Laurence Faivre; Bruno Buecher; Christine Lasset; Marion Gauthier-Villars; Francesca Damiola; Sylvie Mazoyer; Sandrine M Caputo; Nadine Andrieu; Dominique Stoppa-Lyonnet
Journal:  Front Oncol       Date:  2018-10-31       Impact factor: 6.244

5.  Association between polymorphisms in estrogen metabolism genes and breast cancer development in Chinese women: A prospective case-control study.

Authors:  Juanjuan Qiu; Zhenggui Du; Jingping Liu; Yi Zhou; Faqing Liang; Qing Lü
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

6.  A new hybrid record linkage process to make epidemiological databases interoperable: application to the GEMO and GENEPSO studies involving BRCA1 and BRCA2 mutation carriers.

Authors:  Chloé-Agathe Azencott; Maïté Laurent; Catherine Noguès; Nadine Andrieu; Dominique Stoppa-Lyonnet; Yue Jiao; Fabienne Lesueur; Noura Mebirouk; Lilian Laborde; Juana Beauvallet; Marie-Gabrielle Dondon; Séverine Eon-Marchais; Anthony Laugé; Sandrine M Caputo
Journal:  BMC Med Res Methodol       Date:  2021-07-29       Impact factor: 4.615

7.  No Association of Early-Onset Breast or Ovarian Cancer with Early-Onset Cancer in Relatives in BRCA1 or BRCA2 Mutation Families.

Authors:  Marion Imbert-Bouteille; Carole Corsini; Marie-Christine Picot; Lucas Mizrahy; Sandrine Akouete; Helena Huguet; Frédéric Thomas; David Geneviève; Patrice Taourel; Marc Ychou; Virginie Galibert; Chloé Rideau; Karen Baudry; Tatiana Kogut Kubiak; Isabelle Coupier; Rémy Hobeika; Yvette Macary; Alain Toledano; Jérôme Solassol; Antoine Maalouf; Jean-Pierre Daures; Pascal Pujol
Journal:  Genes (Basel)       Date:  2021-07-20       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.